Median time to recovery and discharge of five daysAll patients were at high risk of progression, including four patients who were in the ICU prior to receiving lenzilumabNo treatment emergent adverse events were attributable to lenzilumabJune 15, 2020 07:00 AM Eastern Daylight TimeBURLINGAME, Calif.–(BUSINESS WIRE)–Humanigen, Inc., (HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating cytokine storm with lenzilumab, the company’s proprietary Humaneered® anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody, announced data on the first clinical use of lenzilumab in 12 COVID-19 patients. The manuscript, titled ‘First Clinical Use of Lenzilumab to Neutralize GM-CSF in Patients...